3 Things to Know About Summit Therapeutics' Binary Bet

Key Concepts

• Ansuvimab: A bispecific antibody drug developed by Summit Therapeutics, targeting PD-1 and VEGF pathways.
• Bispecific Antibody: An antibody engineered to bind to two different antigens simultaneously, aiming for synergistic effects.
• PD-1 Drug: A type of immunotherapy that blocks the PD-1 protein, which cancer cells use to evade the immune system. Examples include Keytruda.
• VEGF Drug: A type of drug that inhibits vascular endothelial growth factor, which promotes blood vessel growth that tumors need to survive. Example: Avastin.
• Progression-Free Survival (PFS): The length of time during and after cancer treatment that a patient lives with the disease but it does not get worse.
• Overall Survival (OS): The length of time that patients are still alive after treatment for a disease.
• Non-Small Cell Lung Cancer (NSCLC): A common type of lung cancer.
• Going Concern: A business's ability to continue operating for the foreseeable future.
• Biosimilar: A biological product that is highly similar to a brand-name biological product, with no clinically meaningful differences.

Business Strength

Summit Therapeutics' business strength is rated low by both analysts, with Keith Speights giving it a 4 out of 10 and Karl Thiel a 3 out of 10.

• Core Product: The company's primary focus is Ansuvimab, a bispecific antibody combining PD-1 and VEGF inhibition. The rationale is that the combined effect will be greater than the sum of individual drug actions, similar to combining Keytruda (PD-1) and Avastin (VEGF).
• Unproven Efficacy: While Ansuvimab showed promising results in a study for non-small cell lung cancer (NSCLC), demonstrating superior progression-free survival (PFS) compared to Keytruda, it has yet to show a significant improvement in overall survival (OS).
• Regulatory Risk: Summit hopes for approval based on PFS data alone, but this is unproven. The disappointing OS results from a Phase 3 study in May for Ansuvimab in combination with chemotherapy for NSCLC have negatively impacted the outlook.
• Competitive Landscape: Summit faces significant competition from major pharmaceutical companies like Bantech, Bristol Myers, Merck, and Pfizer, who are also developing similar drugs.
• "One Trick Pony": Both analysts highlight that Summit is heavily reliant on the success of Ansuvimab, making it a "one trick pony."

Management

Management is rated moderately high, with Keith Speights giving a 7 out of 10 and Karl Thiel a 5 out of 10.

• Bob Duggan's Track Record: Bob Duggan, a key figure, is described as an "incredible character" with a unique background in needlepoint and baked goods, and a significant donor to Scientology. Despite lacking a scientific background, he has a history of success with past companies:
  • Computer Motion (sold to Intuitive Surgical)
  • Pharmacyclics (sold to AbbVie for $21 billion)
  • Paradise Bakery (sold to Panera)
• Strategic Pivot and Funding: Summit experienced a significant pivot when it licensed Ansuvimab back in December 2022. This move was facilitated by Duggan's personal wealth ($15 billion), allowing him to personally front the $500 million upfront payment.
• Risk for Investors: While Duggan's past successes are acknowledged, Karl Thiel expresses concern for investors entering the stock now, suggesting they are "walking a tightrope."
• Leadership Concerns: Keith Speights' higher score is attributed to the stock's performance under the co-CEOs, but he cautions that management could resemble "Homer Simpson" if Ansuvimab fails to gain regulatory approval and commercial success.

Financials

Financials receive very low scores, with Keith Speights at 3 out of 10 and Karl Thiel at 2 out of 10.

• Cash Position: Summit has less than $300 million in cash.
• High Burn Rate: The company has a high burn rate, indicating rapid expenditure of cash.
• Going Concern Warning: The company's last 10Q filing stated that its cash is "not sufficient to fund the company's planned operations for a period of at least one year," which is a strong indicator of "going concern" issues.
• Reliance on Personal Wealth: While investors might look to Bob Duggan's personal wealth as a safety net, this is not a reliable factor for investment analysis.
• Comparison to Peers: Karl Thiel notes that his score would be higher if compared solely to other clinical-stage biotech companies, but the Scoreboard's methodology involves broader comparisons.

Valuation

Valuation is considered highly speculative, with Keith Speights projecting a 5% to 10% return and a safety score of 5, while Karl Thiel predicts less than 0% return with a safety score of 2.

• Hinges on Ansuvimab Approval: The stock's performance is entirely dependent on Ansuvimab gaining approval, which in turn relies on demonstrating a statistically significant overall survival benefit.
• Uncertainty of OS Benefit: The outcome of demonstrating OS benefit is uncertain.
• High Current Valuation: Karl Thiel's negative outlook is based on the company's current $14 billion valuation. For Ansuvimab to justify this valuation, it must not only work but also outperform a pipeline of potential competitors.
• Competitive Pressures: The drug could face pressure from oncologists opting to combine existing drugs like Keytruda (which will soon be a biosimilar) and VEGF drugs like Avastin (already available as a biosimilar).

Overall Score and Conclusion

Summit Therapeutics received a low overall score of 3.7 out of 10.

• Synthesis: The analysts agree that Summit Therapeutics is a high-risk, high-reward proposition heavily reliant on the unproven success of its single drug, Ansuvimab. While the management has a history of success and the drug shows promise in PFS, the lack of demonstrated OS benefit, significant competition, and precarious financial situation make it a speculative investment.
• Key Takeaways: Investors should be aware of the substantial regulatory and competitive risks associated with Ansuvimab. The company's financial health is a significant concern, and its valuation appears stretched given the uncertainties. The potential for a large win exists, but the probability of failure is also considerable.